Vivus signs impotence drug deal as proxy vote looms

(Reuters) - Vivus Inc, which is under intense pressure from its top shareholder over its marketing, said it signed a deal worth up to 95 million euros ($121.47 million) with Italy's Menarini Group to introduce its erectile dysfunction drug in Europe, Australia and New Zealand.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news